ProCE Banner Activity

CheckMate 9ER: 3-Yr Follow-up of First-line Nivolumab + Cabozantinib vs Sunitinib in Advanced/Metastatic RCC

Capsule Summary
Conference Coverage
Slideset

With a median follow-up of 44.0 months, nivolumab plus cabozantinib continued to demonstrate a superior OS compared with sunitinib for the first-line treatment of advanced or metastatic RCC.

Released: February 22, 2023

Expiration: February 21, 2024

No longer available for credit.
Begin Activity

Share

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.